Cancer Vaccine Breakthroughs Face Manufacturing Hurdles

The field of cancer vaccines has made significant progress after Merck & Co. and Moderna's personalized melanoma shot scored big in a phase 3 clinical trial, with topline results showing promising efficacy. However, delivering individualized cancer vaccines to the masses will require more than strong clinical results - pharmaceutical manufacturing must adapt.

Amy Walker, CEO of 4basebio, notes that 'the challenge is in the fact that this is n-of-1 production, and it's kind of flipping conventional manufacturing entirely on its head.' The complexity lies in creating synthetic mRNA encoding for patient-specific neoantigens, which requires high-tech computational tools and an enormous scale-out architecture to make tens of thousands of individual batches.

Moderna has already operationalized an automated manufacturing process that produces patient-specific batches of its vaccine intismeran autogene in parallel, with a typical manufacturing turnaround time of a few weeks. The company's purpose-built Marlborough, Massachusetts, facility began supplying clinical batches in September 2025 and is being prepared for a potential commercial launch.